Second-Line CDK4/6 Inhibitors May Be Preferred in Advanced B

First-line use of CDK4/6 inhibitors does not improve most outcomes when compared with second-line use in HR+, HER2- advanced breast cancer.

Related Keywords

Netherlands , Amsterdam , Noord Holland , Gabes Sonke , , Netherlands Cancer Institute ,